ONO PHARMA USA’s Tirabrutinib Receives Orphan Drug Designation from the FDA for the Treatment of Primary Central Nervous System Lymphoma

CAMBRIDGE, Mass., March 23, 2023 /PRNewswire/ — ONO PHARMA USA, INC., announced that its candidate, tirabrutinib (ONO-4059), a Bruton’s tyrosine kinase inhibitor, was granted Orphan Drug Designation on March 21, 2023 by the U.S. Food and Drug Administration (FDA) for the treatment of…